AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.560
-0.090 (-2.47%)
At close: Dec 5, 2025, 4:00 PM EST
3.620
+0.060 (1.69%)
After-hours: Dec 5, 2025, 7:59 PM EST
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 7.75, with a low estimate of 4.00 and a high estimate of 10. The average target predicts an increase of 117.70% from the current stock price of 3.56.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AbCellera Biologics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | +12.36% | Nov 7, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +96.63% | Aug 8, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +180.90% | Jul 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $5 | Buy | Initiates | $5 | +40.45% | Jul 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $10 | Strong Buy | Maintains | $28 → $10 | +180.90% | May 16, 2025 |
Financial Forecast
Revenue This Year
36.17M
from 28.83M
Increased by 25.45%
Revenue Next Year
39.81M
from 36.17M
Increased by 10.07%
EPS This Year
-0.67
from -0.55
EPS Next Year
-0.71
from -0.67
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 38.9M | 60.9M | ||||
| Avg | 36.2M | 39.8M | ||||
| Low | 33.5M | 28.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 34.7% | 68.4% | ||||
| Avg | 25.5% | 10.1% | ||||
| Low | 16.3% | -21.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.63 | -0.65 | ||||
| Avg | -0.67 | -0.71 | ||||
| Low | -0.70 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.